FibroTouch受控衰减参数评价非酒精性脂肪性肝病相关因素分析*

doi:10.3969/j.issn.1672-5069.2015.04.009

Abstract

Abstract: Objective To explore the influencing factors of controlled attenuation parameter （CAP） obtained by FibroTouch in patients with non-alcoholic fatty liver diseases. Methods Fifty-one patients with non-alcoholic fatty liver diseases were recruited in this study，and CAP measurement was conducted by Fibrotouch. Blood lipids， blood biochemical indexes，gender，age and body mass index（BMI） were collected. Multiple linear regression analysis was done for statistic analysis. Results Univariate analysis showed CAP value was positively related to BMI and ALT（P=0.001 for BMI；P=0.036 for ALT）；Multiple linear regression analysis showed that CAP value was significantly correlated with BMI and ALT（F=10.728，P＜0.0001；standard regression coefficient of BMI β=0.505，P=0.000；standard regression coefficient of ALT β=0.254，P=0.040），and the regression equation established after multiple linear regression analysis was CAP=49.547+6.809×BMI+2.82×ALT. Conclusion BMI and serum ALT levels might affect the results of FibroTouch examination in patients with non-alcoholic fatty liver diseases.

Key words: Non-alcoholic fatty liver diseases, Liver steatosis, Fibrotouch, Controlled attenuation parameter, Regression equation

Wang Wenrui，Yang Lanlan，Jia Shengnan，et al.. Influencing factors of controlled attenuation parameter by FibroTouch in patients with non-alcoholic fatty liver diseases[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2015, 18(4): 367-370.

References

[1] Suzuki T，Shinjo S，Arai T，et al. Hypoxia and fatty liver. World J Gastroenterol，2014，20：15087-15097.
[2] Savage DB，Semple RK. Recent insights into fatty liver， metabolic dyslipidaemia and their links to insulin resistance. Curr Opin Lipidol，2010，21：329-336.
[3] Tilg H，Moschen AR. Insulin resistance，inflammation，and non-alcoholic fatty liver disease. Trends Endocrinol Metab，2008，19：371-379.
[4] Dyson JK，Anstee QM，McPherson S，et al. Non-alcoholic fatty liver disease：a practical approach to treatment frontline. Gastroenterology，2014，143：277-286.
[5] Matteoni CA，Younossi ZM，Gramlich T，et al. Non alcoholicfatty liver disease：a spectrum of clinical and pathologicalseverity. Gastroenterology，1999，116：1413-1419.
[6] Wanless IR，Lentz JS. Fatty liver hepatitis（steatohepatitis） andobesity：an autopsy study with analysis of risk factors.Hepatology，1990，12：1106-1110.
[7] Williams CD，Stengel J，Asike MI，et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy：a prospective study. Gastroenterology，2011，140：124-131. [8] Sasso M，Beaugrand M，de Ledinghen V，et al. Controlled attenuation parameter（CAP）：a novel VCTE guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis： preliminary study and validation in a cohort of patients with chronic liver disease from various causes. Ultrasound Med Biol，2010，36：1825-1835.
[9] Myers RP，Pollett A，Kirsch R，et al. Controlled attenuation parameter（CAP）：a noninvasive method for the detection of hepatic steatosis based on transient elastography. Liver Int，2012，32：902-910.
[10] Kumar M，Rastogi A，Singh T，et al. Controlled attenuation parameter for non-invasive assessment of hepatic steatosis：Does etiology affect performance. J Gastroenterol Hepatol，2013， 28：1194-1201.
[11] Shen F. Controlled attenuation parameter for non-invasive assessment of hepatic steatosis in Chinese patients. World J Gastroenterol，2014，20：4702-4711.
[12] 卢加发，潘勤，范建高，等普通人群肝脏受控衰减参数的多元回归分析.实用肝脏病杂志，2014，17（3）：291-294.
[13] Kim W R，Steven L F，Adrian M D，et al. Serum activity of alanine aminotransferas（ALT） as an indicator of health and disease. Hepatology，2008，47：1363-1370.
[14] Henderson NC，Iredalc JP. Liver fibrosis：cellular mechanism of progression and resolution. Clin Sci，2007，112：265-280.
[15] Ma X，Holalkere NS，Kambadakone R A，et al. Imaging-based quantification of hepatic fat：methods and clinical applications. Radiographics，2009，29：1253-1277.
[16] Sasso M，Tengher-Barna I，Ziol M，et al. Novel controlled attenuation parameter for noninvasive assessment of steatosis using Fibroscan（R）：validation in chronic hepatitis C. J Viral Hepat，2012，19：244-253.
[17] Jung KS，Kim BK，Kim SU，et al. Factors affecting the accuracy of controlled attenuation parameter （CAP） in assessing hepatic steatosis in patients with chronic liver disease. PLoS One. 2014，9（6）：23141.
[18] de Ledinghen V，Vergniol J，Foucher J，et al. Noninvasive diagnosis of liver steatosis using controlled attenuation parameter （CAP） and transient elastography. Liver Int，2012，32：911-918.
[19] Wong GL. Transient elastography：Kill two birds with one stone World J Hepatol，2013，27：264-274.
[20] Chon YE，Jung KS，Kim SU，et al. Controlled attenuation parameter（CAP） for detection of hepatic steatosis in patients with chronic liver diseases：a prospective study of a native Korean population. Liver Int，2013，34：102-109.
[21] 郭斯敏，谢青. 非酒精性脂肪性肝病的无创性诊断方法及检测系统的研究进展. 实用肝脏病杂志，2008，11（4）：279-283.
[22] 非酒精性脂肪性肝病诊疗指南（2010 年修订版）. 中华肝脏病杂志，2010，（3）：163-166.
[23] Masaki K，Takaki S，Hyogo H，et al. Utility of controlled attenuation parameter measurement for assessing liver steatosis in Japanese patients with chronic liver diseases. Hepatol Res， 2013，43（11）：1182-1189.
[24] 沈峰，徐正婕，范建高，等. FibroScanR 实施受控衰减参数评价脂肪肝的影响因素及重复性分析. 实用肝脏病杂志，2013，16（1）：59-62.

Influencing factors of controlled attenuation parameter by FibroTouch in patients with non-alcoholic fatty liver diseases

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Gao Wei, Hou Yong. Diagnostic efficacy of hepatic fibrosis by liver stiffness measurement in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 652-655.
[2]	Wang Yan, Su Feng, Li Yuanyuan, et al. Protective effect of bee venom hemolysin on rats with nonalcoholic fatty liver disease [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 474-477.
[3]	Xie Xiao, Liu Ting, Dong Zhixia, et al. Value of controlled attenuation parameter in diagnosis of individuals with liver steatosis by using Fibrotouch [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 526-529.
[4]	Cui Qinghua, Tao Hong, Wang Xiaoyue, et al.. Changes of serum glycosylated hemoglobin level and cardiac functions in patients with non-alcoholic fatty liver disease [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 69-72.
[5]	Dong Xuelian, Zhang Wenjun.. Application of controlled attenuation parameter in screening individuals with risk of metabolic syndrome [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 868-871.
[6]	Liu Yanghe, Long Dengyi, Bei Zheng, et al. Efficacy of bacillus subtilis duplex and polyene phosphatidylcholine combination in treatments of patients with nonalcoholic fatty liver diseases [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(4): 573-576.
[7]	Yang Huimin, Jiang Chunyan. Clinical efficacy of herbal medicine and silibinin in the treatment of patients with nonalcoholic fatty liver diseases [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(3): 467-468.
[8]	Wang Qian,Guo Ping. Application of fibroscan and anthropometric parameters in diagnosis of patients with nonalcoholic fatty liver diseases [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2017, 20(6): 754-755.
[9]	Yu Hongyan, Di Fusheng. Endocrinologists should pay attention to the outcome of liver diseases in patients with diabetes and non-alcoholic fatty liver diseases [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2017, 20(3): 267-270.
[10]	Zhao Wenxia，Zhang Lihui.. Application of Chinese traditional medicine in the treatment of patients with non-alcoholic fatty liver diseases [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2017, 20(2): 132-134.
[11]	Sun Changgui， Zeng Jing，Sun Wanlu，et al.. Changes of estimated glomerular filtration rates in healthy check-up adults with nonalcoholic fatty liver diseases [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2017, 20(2): 165-170.
[12]	Zeng Jing, Chen Guangyu, Pan Qin, e t al. Detection of controlled attenuation parameter of spleen in diagnosis of fatty liver diseases [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2016, 19(4): 445-450.
[13]	Zhu Chanyan,Qu Jichen,Cao Haixia,et al.. Incidence of metabolic syndrome and non-alcoholic fatty liver diseases in patients with different histological types of lung cancer [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2016, 19(3): 288-291.
[14]	Zhong Bihui. Appropriate application of lipid-regulating agents in patients with non-alcoholic fatty liver diseases [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2016, 19(2): 143-146.
[15]	Yan Jinsong, Yuan Dan, Li Dongsheng. Risk factors of non-alcoholic fatty liver in patients with diabetes type two [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2016, 19(2): 212-213.